The Effect of Immunonutrition on Postoperative Ileus Following Colorectal Cancer Surgery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Why It Matters

Accelerating bowel function and cutting complications can shrink hospital costs and improve recovery pathways such as ERAS, directly impacting surgical outcomes and healthcare expenditures.

Key Takeaways

• Immunonutrition shortens first flatus time by 0.56 days.
• First defecation occurs roughly half a day earlier.
• Hospital discharge accelerated by about 1.5 days.
• Overall complications reduced 36% (RR 0.64) with immunonutrition.
• Postoperative ileus rates unchanged; pooled RR 0.73 not significant.

Pulse Analysis

Immunonutrition, which blends arginine, glutamine, and omega‑3 fatty acids, is gaining traction as a peri‑operative adjunct for colorectal cancer surgery. The meta‑analysis pooled data from diverse geographic regions, revealing consistent gains in early gastrointestinal milestones—key drivers of patient comfort and discharge readiness. By trimming the interval to first flatus and first stool by roughly half a day, clinicians can reduce reliance on nasogastric decompression and opioid analgesia, both known contributors to delayed motility. The aggregate reduction of 1.5 days in length of stay translates into sizable cost savings, especially in the United States where postoperative ileus alone incurs over $1.4 billion annually.

Beyond speedier recovery, the study highlights a 36 percent drop in overall postoperative complications, underscoring immunonutrition’s broader immunomodulatory effects. Glutamine fuels enterocytes, arginine supports nitric‑oxide‑mediated microcirculation, and omega‑3s dampen inflammatory cytokines, collectively preserving mucosal integrity and curbing infection risk. These mechanisms dovetail with Enhanced Recovery After Surgery (ERAS) protocols, suggesting that integrating immunonutrition could amplify existing pathway benefits without substantial protocol overhaul.

Nevertheless, the analysis did not demonstrate a statistically significant impact on the incidence of postoperative ileus itself, reflecting heterogeneity in trial designs, nutrient formulations, and ileus definitions. Future large‑scale, multicenter trials should standardize dosing schedules, clarify patient sub‑groups—such as the elderly or malnourished—and adopt uniform ileus criteria. If these gaps are addressed, immunonutrition may become a cornerstone of evidence‑based peri‑operative care, delivering both clinical and economic advantages for colorectal cancer surgery patients.